In conclusion, these findings suggest that IL-2RA induction with early intensified EC-MPS dosing and CNI therapy in de novo kidney transplant patients at low immunological risk is associated with nonsignificant difference in efficacy at three years after transplant whether oral steroids are withheld or administered for at least three months. The gene discussed is IL2RA; the disease is medical procedure.